CDXS Codexis, Inc.

NASDAQ
$1.15

Codexis, Inc. (CDXS) is expected to report earnings on February 11, 2027, after the market close. The consensus earnings estimate is a loss of $0.04 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +1.8% since its last earnings release on November 12, 2026.

Codexis Beat Consensus Estimates, Reaffirms Revenue Guidance
Thursday, November 12, 2026 · 4:05 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 11
Thursday · 4:05 PM ET
Earnings Whisper
-
vs ($0.04)
Rev est $24.87M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.12

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Codexis, Inc.

Codexis Inc is a developer of proprietary biocatalysts, which are enzymes or microbes that initiate or accelerate chemical reactions. It has recently started to use its technology to develop biocatalysts for use in the fine chemicals markets.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.